Overview
Sweden biologics firm's Q1 revenue rose 167% yr/yr
Q1 EBITDA and EBIT losses narrowed yr/yr
Company advancing Hammenhög asset sale with two prospective buyers
Outlook
Simris expects to decide on strategic direction for ADC development during second qtr 2026
Company advancing divestment process for Hammenhög assets, expects sale to strengthen finances
Simris evaluating options to expand ADC-payload programme, both requiring additional funding
Result Drivers
ADC PAYLOAD DEVELOPMENT - Co said it initiated new preclinical studies on its proprietary Microcystin-based ADC payload platform to advance innovation and support lead-candidate selection
Company press release: ID:nMFN1gttgS
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
SEK 424,000
Q1 EBIT
-SEK 5.63 mln
Q1 EBITDA
-SEK 2.18 mln
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)